We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ironwood beat Q2 earnings estimates and raised 2026 revenue guidance on stronger Linzess demand.
IRWD posted Q2 revenues of $113 million, missing the $120 million consensus despite 32.6% y/y growth.
IRWD raised its 2026 revenue outlook to $460-$485 million and adjusted EBITDA to more than $310 million.
Ironwood Pharmaceuticals (IRWD - Free Report) reported adjusted earnings of 31 cents per share for the second quarter of 2026, surpassing the Zacks Consensus Estimate of 26 cents. The company had reported adjusted earnings of 14 cents per share in the year-ago quarter.
Total revenues in the second quarter were $113 million, which missed the Zacks Consensus Estimate of $120 million. Revenues, however, surged by around 32.6% year over year.
Year to date, shares of Ironwood have risen 26.4% against the industry’s decline of 3.7%.
Image Source: Zacks Investment Research
IRWD's Q2 Earnings in Details
As reported by its partner AbbVie (ABBV - Free Report) , Ironwood’s sole marketed product, Linzess (linaclotide), generated net sales of $282.3 million in the United States, up 14% year over year. Linzess sales were boosted by higher demand and better pricing, helped by the removal of inflation-related rebates and the favorable timing of rebate adjustments.
Total prescription demand for Linzess increased 4% year over year during the second quarter.
IRWD and ABBV share Linzess’ brand collaboration profits and losses equally.
Ironwood’s share of net profit from sales of Linzess in the United States (included in collaborative revenues) totaled $110 million, reflecting a 28% year-over-year increase.
Ironwood also has agreements with two partners, Astellas Pharma and AstraZeneca (AZN - Free Report) , related to the development and commercialization of Linzess in Japan and China, respectively.
Astellas and AstraZeneca have exclusive rights to develop and market the drug in their respective territories. Both companies are liable to pay royalties to Ironwood on net Linzess revenues earned in their regions.
Ironwood's royalties and other revenues were $3 million in the second quarter of 2026. In the year-ago quarter, the company recorded royalties and other revenues of negative $0.5 million.
Total cost and expenses (including research and development expenses, selling, general and administrative expenses and restructuring expenses) in the second quarter were $33.7 million, down 15.5% from the year-ago quarter.
Ironwood recorded adjusted EBITDA of $83 million in the reported quarter, up 65.7% year over year.
As of June 30, 2026, Ironwood had cash and cash equivalents worth $79.1 million compared with $220.5 million as of March 31, 2026.
IRWD's 2026 Guidance
Ironwood raised its full-year 2026 revenue guidance, reflecting higher demand for Linzess.
The company now expects total revenues to be in the range of $460 to $485 million in 2026 compared with the previous expectation of $450 to $475 million.
U.S. sales of Linzess (to be recorded by AbbVie) are now expected to be in the range of $1.15-$1.20 billion versus the earlier projection of $1.13-$1.18 billion in 2026.
Ironwood now expects to deliver an adjusted EBITDA of more than $310 million in 2026, indicating effective cost management. Previously, the company expected to deliver an adjusted EBITDA of more than $300 million.
IRWD's Recent Key Updates
In May 2026, the FDA approved the expanded use of Linzess for the treatment of functional constipation (FC) in pediatric patients aged two years and older. The therapy was previously approved for FC in children and adolescents aged six to 17 years. Linzess is the only FDA-approved daily treatment for pediatric FC.
Linzess is already approved for the treatment of irritable bowel syndrome with constipation in adults and pediatric patients aged seven years and above. The drug is also approved for chronic idiopathic constipation in adults.
Ironwood is developing its next-generation GLP-2 analog, apraglutide, for treating patients with short bowel syndrome (“SBS”) with intestinal failure (“IF”) who are dependent on parenteral support (“PS”).
The confirmatory phase III STARS-2 study evaluating apraglutide in short bowel syndrome with intestinal failure (SBS-IF) is now actively recruiting patients. The primary endpoint of the STARS-2 study will check the relative change from baseline in actual weekly PS volume at week 24 in the given patient population.
Ironwood acquired the rights to develop and commercialize apraglutide following the acquisition of VectivBio in June 2023.
Ironwood Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 159.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised
Key Takeaways
Ironwood Pharmaceuticals (IRWD - Free Report) reported adjusted earnings of 31 cents per share for the second quarter of 2026, surpassing the Zacks Consensus Estimate of 26 cents. The company had reported adjusted earnings of 14 cents per share in the year-ago quarter.
Total revenues in the second quarter were $113 million, which missed the Zacks Consensus Estimate of $120 million. Revenues, however, surged by around 32.6% year over year.
Year to date, shares of Ironwood have risen 26.4% against the industry’s decline of 3.7%.
Image Source: Zacks Investment Research
IRWD's Q2 Earnings in Details
As reported by its partner AbbVie (ABBV - Free Report) , Ironwood’s sole marketed product, Linzess (linaclotide), generated net sales of $282.3 million in the United States, up 14% year over year. Linzess sales were boosted by higher demand and better pricing, helped by the removal of inflation-related rebates and the favorable timing of rebate adjustments.
Total prescription demand for Linzess increased 4% year over year during the second quarter.
IRWD and ABBV share Linzess’ brand collaboration profits and losses equally.
Ironwood’s share of net profit from sales of Linzess in the United States (included in collaborative revenues) totaled $110 million, reflecting a 28% year-over-year increase.
Ironwood also has agreements with two partners, Astellas Pharma and AstraZeneca (AZN - Free Report) , related to the development and commercialization of Linzess in Japan and China, respectively.
Astellas and AstraZeneca have exclusive rights to develop and market the drug in their respective territories. Both companies are liable to pay royalties to Ironwood on net Linzess revenues earned in their regions.
Ironwood's royalties and other revenues were $3 million in the second quarter of 2026. In the year-ago quarter, the company recorded royalties and other revenues of negative $0.5 million.
Total cost and expenses (including research and development expenses, selling, general and administrative expenses and restructuring expenses) in the second quarter were $33.7 million, down 15.5% from the year-ago quarter.
Ironwood recorded adjusted EBITDA of $83 million in the reported quarter, up 65.7% year over year.
As of June 30, 2026, Ironwood had cash and cash equivalents worth $79.1 million compared with $220.5 million as of March 31, 2026.
IRWD's 2026 Guidance
Ironwood raised its full-year 2026 revenue guidance, reflecting higher demand for Linzess.
The company now expects total revenues to be in the range of $460 to $485 million in 2026 compared with the previous expectation of $450 to $475 million.
U.S. sales of Linzess (to be recorded by AbbVie) are now expected to be in the range of $1.15-$1.20 billion versus the earlier projection of $1.13-$1.18 billion in 2026.
Ironwood now expects to deliver an adjusted EBITDA of more than $310 million in 2026, indicating effective cost management. Previously, the company expected to deliver an adjusted EBITDA of more than $300 million.
IRWD's Recent Key Updates
In May 2026, the FDA approved the expanded use of Linzess for the treatment of functional constipation (FC) in pediatric patients aged two years and older. The therapy was previously approved for FC in children and adolescents aged six to 17 years. Linzess is the only FDA-approved daily treatment for pediatric FC.
Linzess is already approved for the treatment of irritable bowel syndrome with constipation in adults and pediatric patients aged seven years and above. The drug is also approved for chronic idiopathic constipation in adults.
Ironwood is developing its next-generation GLP-2 analog, apraglutide, for treating patients with short bowel syndrome (“SBS”) with intestinal failure (“IF”) who are dependent on parenteral support (“PS”).
The confirmatory phase III STARS-2 study evaluating apraglutide in short bowel syndrome with intestinal failure (SBS-IF) is now actively recruiting patients. The primary endpoint of the STARS-2 study will check the relative change from baseline in actual weekly PS volume at week 24 in the given patient population.
Ironwood acquired the rights to develop and commercialize apraglutide following the acquisition of VectivBio in June 2023.
Ironwood Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Ironwood Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Ironwood Pharmaceuticals, Inc. Quote
IRWD’s Zacks Rank & Stock to Consider
Ironwood currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is Liquidia Corporation (LQDA - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 159.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.